Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma

Trial Profile

Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results (n=48) assessing safety of high-dose ipilimumab and the combination of nivolumab plus ipilimumab in patients with uveal melanoma, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 04 Oct 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
    • 28 May 2015 According to the ClinicalTrials.gov record, planned number of patients changed from 141 to 52.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top